HK1203364A1 - Use of n-hydroxysuccinimide to improve conjugate stability - Google Patents

Use of n-hydroxysuccinimide to improve conjugate stability Download PDF

Info

Publication number
HK1203364A1
HK1203364A1 HK15103864.0A HK15103864A HK1203364A1 HK 1203364 A1 HK1203364 A1 HK 1203364A1 HK 15103864 A HK15103864 A HK 15103864A HK 1203364 A1 HK1203364 A1 HK 1203364A1
Authority
HK
Hong Kong
Prior art keywords
hydroxysuccinimide
nhs
conjugate stability
improve conjugate
improve
Prior art date
Application number
HK15103864.0A
Other languages
English (en)
Chinese (zh)
Inventor
Fang Liu
Godfrey W. Amphlett
Deborah H. Meshulam
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of HK1203364A1 publication Critical patent/HK1203364A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15103864.0A 2011-12-13 2012-12-13 Use of n-hydroxysuccinimide to improve conjugate stability HK1203364A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161570139P 2011-12-13 2011-12-13
US61/570,139 2011-12-13
PCT/US2012/069527 WO2013090590A1 (en) 2011-12-13 2012-12-13 Use of n-hydroxysuccinimide to improve conjugate stability

Publications (1)

Publication Number Publication Date
HK1203364A1 true HK1203364A1 (en) 2015-10-30

Family

ID=48613179

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103864.0A HK1203364A1 (en) 2011-12-13 2012-12-13 Use of n-hydroxysuccinimide to improve conjugate stability

Country Status (14)

Country Link
US (1) US20140350228A1 (https=)
EP (1) EP2790724A4 (https=)
JP (1) JP2015504869A (https=)
KR (1) KR20140107418A (https=)
CN (1) CN104093425A (https=)
AU (1) AU2012352210A1 (https=)
BR (1) BR112014014464A8 (https=)
CA (1) CA2859444A1 (https=)
EA (1) EA201491173A1 (https=)
HK (1) HK1203364A1 (https=)
IL (1) IL233086A0 (https=)
MX (1) MX2014007125A (https=)
SG (2) SG11201403179QA (https=)
WO (1) WO2013090590A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
BRPI1010620B8 (pt) 2009-06-03 2021-05-25 Immunogen Inc métodos de conjugação
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
CN106267225B (zh) * 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
CN109152845B (zh) 2016-04-14 2022-07-12 宝力泰锐克斯有限公司 含有在环内包含至少两个(-ch2-ch2-o-)单元的接头的缀合物和缀合试剂
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
CN113336823A (zh) * 2021-05-28 2021-09-03 联宁（苏州）生物制药有限公司 一种用于抗体偶联药物连接子lnd1067的合成方法
WO2025151380A1 (en) * 2024-01-08 2025-07-17 Azvlz, Inc. Functionalized conjugation crosslinkers and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835829B1 (fr) * 2002-02-13 2007-09-14 Centre Nat Rech Scient Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
EP3539572A1 (en) * 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
EP2298308B1 (en) * 2005-11-14 2013-01-16 University Of Southern California Integrin-binding small molecules
PL2019104T3 (pl) * 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
CN102365021B (zh) * 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
BRPI1010620B8 (pt) * 2009-06-03 2021-05-25 Immunogen Inc métodos de conjugação

Also Published As

Publication number Publication date
SG11201403179QA (en) 2014-07-30
US20140350228A1 (en) 2014-11-27
SG10201604747WA (en) 2016-08-30
CN104093425A (zh) 2014-10-08
EA201491173A1 (ru) 2014-11-28
MX2014007125A (es) 2015-04-16
IL233086A0 (en) 2014-07-31
EP2790724A1 (en) 2014-10-22
WO2013090590A1 (en) 2013-06-20
BR112014014464A2 (pt) 2017-06-13
EP2790724A4 (en) 2015-08-05
CA2859444A1 (en) 2013-06-20
KR20140107418A (ko) 2014-09-04
AU2012352210A1 (en) 2014-07-24
BR112014014464A8 (pt) 2017-06-13
JP2015504869A (ja) 2015-02-16

Similar Documents

Publication Publication Date Title
HK1203364A1 (en) Use of n-hydroxysuccinimide to improve conjugate stability
NZ741211A (en) Self-stabilizing linker conjugates
MX339927B (es) Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
WO2012135517A3 (en) Preparation of maytansinoid antibody conjugates by a one-step process
MX343337B (es) Metodos de preparacion de conjugados.
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2018098269A3 (en) Peptide-containing linkers for antibody-drug conjugates
EA201490095A1 (ru) Новые производные майтанзиноида с пептидным линкером и их конъюгаты
IL217208A (en) History of cryptophycin, critophycin conjugates, processes for their preparation, and their use as anticancer agents
WO2013033438A3 (en) Nanoparticle peg modification with h-phosphonates
WO2014097099A3 (en) Glycoconjugation process
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
WO2012061607A3 (en) Compositions comprising functionalized carbon-based nanostructures and related methods
MX2013014583A (es) Conjugados de proteina-polimero-farmaco.
WO2013103301A3 (en) Method for preparing cell targeting conjugates, and the complexes obtained
MY167579A (en) Glycoconjugation processes and compositions
MX2015002482A (es) Composicion inmunogenica.
EA201391400A1 (ru) Способ производства конъюгатов с улучшенной гомогенностью
WO2009086824A3 (de) Magnetische transducer
CA2902372C (en) Polymer conjugate for delivery of a bioactive agent
WO2010031720A3 (en) Novel antibody formulation
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
WO2014194030A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
TW200942530A (en) Pyridine compounds
WO2015073575A3 (en) Residualizing linkers and uses thereof